(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

https://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

https://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






91 Result: Design

Sage Therapeutics' SAGE-718 Gets FDA ODD; Bullish View On TeraWulf

October 18th, 2023

Shares of Sage Therapeutics, Inc. (Nasdaq: SAGE), a leading biopharmaceutical company specializing in neurological and neuropsychiatric disorders, surged over 5% in pre-market trading after the company said that the U.S. Food and Drug Administration . Read more

S&P MidCap 400 Boosts Floor & Decor; United Airlines Tops Estimates, Outlook Falls Short

October 17th, 2023

Floor & Decor Holdings Inc. (NYSE: FND) is set to replace Vicor Corp. (Nasdaq: VICR) in the S&P MidCap 400 index, effective October 20, 2023 prior to the open of trading. The S&P MidCap 400 index serves as a benchmark for mid-sized companies, desi. Read more

Momentum: Tempest Therapeutics Rides High on TPST-1120 Clinical Data

October 11th, 2023

Shares of Tempest Therapeutics, Inc. (Nasdaq: TPST) surged by more than 400% in pre-market trading due to strong clinical results for TPST-1120 in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma. In a . Read more

Market Buzz: CDI Trial Outcome Fuels Acurx Pharmaceuticals

October 02nd, 2023

Shares of Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) surged by more than 20% in pre-market trading following the company's decision to discontinue its Phase 2b clinical trial of ibezapolstat, its lead antibiotic candidate, designed for the treatment . Read more

FDA Clearance Sparks Femasys Surge; THOR Industries Tops Estimates

September 25th, 2023

Shares of Femasys Inc. (Nasdaq: FEMY) surged by over 100% in after-hours trading following the company's announcement of receiving 510(k) Clearance from the United States Food and Drug Administration (FDA) for its groundbreaking infertility treatment. Read more

TD SYNNEX, Progress Software, and MillerKnoll's Earnings: A Preview

September 23rd, 2023

On Tuesday, September 26, several companies are set to reveal their financial performance, including: TD SYNNEX Corporation (NYSE: SNX), a corporation specializing in IT distribution and services, is scheduled to announce its third-quarter fiscal . Read more

Breaking News: AMC's $325.5M Equity Raise and Draganfly's Defense Orders

September 14th, 2023

AMC Entertainment Holdings, Inc. (NYSE: AMC) said that it successfully raised approximately $325.5 million in new equity capital by selling 40 million shares at an average price of around $8.14 per share, before commissions and fees. $AMC was trad. Read more

Semtech Posts Upbeat Results, Outlook Falls Short; FDA Panel Backs Alnylam's Patisiran

September 13th, 2023

Semtech Corporation (Nasdaq: SMTC), a technology company specializing in semiconductor solutions, reported earnings of $0.11 per share for the second quarter of fiscal 2024, surpassing the consensus EPS estimate of $0.02. Quarterly sales for Semtech . Read more

Spirit Airlines Lowers Outlook; Alnylam Stock Halted Amid FDA Panel Review

September 13th, 2023

Shares of Spirit Airlines, Inc. (NYSE: SAVE) experienced a dip in pre-market trading as it revised downwardly its third-quarter 2023 outlook. The company now anticipates revenues between $1.245 billion and $1.255 billion, a notable decrease from its . Read more

Momentum: Crinetics' Acromegaly Study Data and Tesla's Morgan Stanley Boost

September 11th, 2023

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) has reported promising results from its Phase 3 PATHFNDR-1 study evaluating paltusotine, an oral once-daily investigational compound designed for acromegaly treatment. The study achieved its primary endp. Read more

Breaking: NIO Misses Q2 Expectations; 3M Settles Litigation for $6B

August 29th, 2023

NIO Inc. (NYSE: NIO), an electric vehicle manufacturer, reported a second-quarter 2023 loss of $(0.45) per American depositary share, falling short of the consensus estimate loss of $(0.36) per share. The company's quarterly sales amounted to $1.21 b. Read more

S&P SmallCap 600 Boosts Goosehead Insurance and Jackson Financial

August 28th, 2023

S&P Dow Jones Indices has announced changes to the S&P SmallCap 600. Goosehead Insurance Inc. (Nasdaq: GSHD) will take the place of NuVasive Inc. (Nasdaq: NUVA), and Jackson Financial Inc. (NYSE: JXN) will replace NexTier Oilfield Solutions Inc. (NYS. Read more

Lockheed Martin Lands $2.77B+ Contract Modification; Domo Q2 Beats Street, Outlook Falls Short

August 24th, 2023

Sikorsky Aircraft Corp., a Lockheed Martin Corporation (NYSE: LMT) subsidiary, has secured a $2,774,583,756 fixed-price incentive (firm-target), firm-fixed-price modification to a previous contract. This modification encompasses Lots 7 and 8 block bu. Read more

Autodesk Beats Estimates; Weibo Posts Mixed Results

August 24th, 2023

Autodesk, Inc. (Nasdaq: ADSK), a leading software solutions provider for the design and engineering industries, reported second-quarter fiscal 2024 earnings of $1.91 per share, exceeding the consensus EPS estimate of $1.72. The company's quarterly sa. Read more

NVIDIA, Analog Devices, and Autodesk Earnings On Deck: What to Expect

August 20th, 2023

A selection of companies slated to release their financial results on Wednesday, August 23, includes: NVIDIA Corporation (Nasdaq: NVDA), a leading name in the technology sector, is set to unveil its financial results for the second quarter of fisc. Read more

Load More Content